Advaxis, Inc. (NASDAQ:ADXS) fell 7.2% during trading on Friday . The company traded as low as $2.91 and last traded at $2.95. 1,274,373 shares changed hands during mid-day trading, an increase of 30% from the average session volume of 981,665 shares. The stock had previously closed at $3.18.

A number of research firms have commented on ADXS. ValuEngine downgraded Advaxis from a “sell” rating to a “strong sell” rating in a report on Tuesday, October 3rd. Cantor Fitzgerald set a $19.00 target price on Advaxis and gave the company a “buy” rating in a report on Friday, December 22nd. Finally, HC Wainwright reissued a “buy” rating and issued a $23.00 target price on shares of Advaxis in a report on Wednesday, November 8th.

The company has a market capitalization of $120.28, a price-to-earnings ratio of -1.28 and a beta of 1.91.

Advaxis (NASDAQ:ADXS) last released its earnings results on Wednesday, December 20th. The biotechnology company reported ($0.57) EPS for the quarter, missing analysts’ consensus estimates of ($0.55) by ($0.02). Advaxis had a negative net margin of 776.63% and a negative return on equity of 114.00%. The business had revenue of $1.76 million during the quarter, compared to analyst estimates of $3.05 million. sell-side analysts anticipate that Advaxis, Inc. will post -2.36 EPS for the current fiscal year.

In other news, insider Robert Petit sold 12,625 shares of the firm’s stock in a transaction on Thursday, November 2nd. The stock was sold at an average price of $3.19, for a total value of $40,273.75. Following the completion of the transaction, the insider now owns 237,265 shares in the company, valued at $756,875.35. The sale was disclosed in a document filed with the SEC, which is available at this link. Also, CFO Sara Bonstein sold 12,734 shares of the firm’s stock in a transaction on Thursday, November 2nd. The shares were sold at an average price of $3.19, for a total value of $40,621.46. Following the completion of the transaction, the chief financial officer now owns 244,504 shares of the company’s stock, valued at approximately $779,967.76. The disclosure for this sale can be found here. In the last 90 days, insiders sold 38,192 shares of company stock valued at $122,615. Company insiders own 7.21% of the company’s stock.

Several hedge funds have recently made changes to their positions in ADXS. Schwab Charles Investment Management Inc. increased its position in shares of Advaxis by 0.6% in the second quarter. Schwab Charles Investment Management Inc. now owns 129,321 shares of the biotechnology company’s stock valued at $840,000 after buying an additional 817 shares in the last quarter. Rhumbline Advisers increased its position in shares of Advaxis by 3.7% in the second quarter. Rhumbline Advisers now owns 42,508 shares of the biotechnology company’s stock valued at $276,000 after buying an additional 1,530 shares in the last quarter. Wells Fargo & Company MN increased its position in shares of Advaxis by 2.6% in the second quarter. Wells Fargo & Company MN now owns 44,813 shares of the biotechnology company’s stock valued at $290,000 after buying an additional 1,144 shares in the last quarter. Alliancebernstein L.P. increased its position in shares of Advaxis by 44.8% in the second quarter. Alliancebernstein L.P. now owns 67,900 shares of the biotechnology company’s stock valued at $441,000 after buying an additional 21,000 shares in the last quarter. Finally, Teachers Advisors LLC increased its position in shares of Advaxis by 5.1% in the second quarter. Teachers Advisors LLC now owns 69,428 shares of the biotechnology company’s stock valued at $451,000 after buying an additional 3,369 shares in the last quarter. Institutional investors and hedge funds own 42.89% of the company’s stock.

ILLEGAL ACTIVITY WARNING: This news story was first published by Watch List News and is the property of of Watch List News. If you are viewing this news story on another website, it was stolen and reposted in violation of United States & international trademark & copyright law. The original version of this news story can be accessed at https://www.watchlistnews.com/advaxis-adxs-stock-price-down-7-2/1826607.html.

About Advaxis

Advaxis, Inc is a clinical-stage biotechnology company focused on the discovery, development and commercialization of Listeria monocytogenes (Lm)-Listeriolysin O (LLO) cancer immunotherapies. These immunotherapies are based on a platform technology that utilizes live attenuated Lm bioengineered to secrete antigen/adjuvant fusion proteins.

Receive News & Ratings for Advaxis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Advaxis and related companies with MarketBeat.com's FREE daily email newsletter.